One of the most promising areas of cancer research is personalised therapy using precision medicine.

The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumours to therapies based on the tumour's genetic characteristics.

This effort addresses therapeutic efficacy across multiple tissues, but also adds data as to the clinical value of broad-based screening panels versus disease-specific assays.

A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumour tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

These results are noteworthy because, to date, concerns have been widely expressed about the complexity, accuracy, and reproducibility of next-generation sequencing (NGS) for application in clinical trials.

These results clearly show that locked and controlled procedures permit reliable, accurate, and reproducible use of NGS for clinical purposes.

Ultimately, the NCI-MATCH trial aims to evaluate tumour biopsy specimens from about 6,000 patients.

The NGS technology used in the trial (the Oncomine Cancer Panel assay and the Personal Genome Machine from Thermo Fisher Scientific) is able to detect more than 4,000 pre-defined genomic variations across 143 genes, including single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and gene fusions.

Levels of evidence were developed to select a subset of specific actionable genomic variants to be used for treatment matching.

The investigators report that the assay was highly sensitive (96.98% for 265 known mutations), with 99.99% specificity.

Since one feature of the NCI-MATCH trial is the wide variety of tumours examined, including solid tumours and lymphomas that no longer respond to standard therapy, the assay used must be able to analyse specimens from different tissues.

Importantly, the NCI-MATCH NGS assay was able to accurately determine genetic abnormalities in biopsies from the pancreas, melanoma, bone, and skin.

One-hundred and eighty-six samples and 12 cell lines were tested at four different laboratories.

Steps were taken to maximise standardisation, including development of standard operating procedures, use of the same commercial assay and instruments, and face-to-face discussions.

The investigators found that the assay results were highly reproducible, with the same results across multiple laboratories.

This is critical for future clinical use leading to improved patient outcomes.

"The validation study reported by Williams and colleagues is another step moving the field closer to the time when precision medicine will generate the expected benefits in improved clinical outcomes," commented Elizabeth R. Unger, PhD, MD, of the Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention (Atlanta, GA). "Although the success of the NCI-MATCH trial cannot be assured, linking precision laboratories to precision medicine trials assures that data used for drug assignment will be reliable. Further, the use of a commercial platform and integrated analysis and reporting pipeline will greatly facilitate broader translation of any successes."

Source: Journal of Molecular Diagnostics